Circulation. 2021;143:583–596. DOI: 10.1161/CIRCULATIONAHA.120.050438 February 9, 2021 583 Circulation Dominick J. Angiolillo , MD, PhD Deepak L. Bhatt , MD, MPH Christopher P. Cannon, MD John W. Eikelboom, MD C. Michael Gibson, MD Shaun G. Goodman , MD Christopher B. Granger , MD David R. Holmes , MD Renato D. Lopes , MD, PhD Roxana Mehran , MD David J. Moliterno, MD Matthew J. Price, MD Jacqueline Saw , MD Jean-Francois Tanguay, MD David P. Faxon, MD https://www.ahajournals.org/journal/circ The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association. Key Words: anticoagulants ◼ antiplatelets ◼ atrial fibrillation ◼ stents © 2021 American Heart Association, Inc. ABSTRACT: A growing number of patients undergoing percutaneous coronary intervention (PCI) with stent implantation also have atrial fibrillation. This poses challenges for their optimal antithrombotic management because patients with atrial fibrillation undergoing PCI require oral anticoagulation for the prevention of cardiac thromboembolism and dual antiplatelet therapy for the prevention of coronary thrombotic complications. The combination of oral anticoagulation and dual antiplatelet therapy substantially increases the risk of bleeding. Over the last decade, a series of North American Consensus Statements on the Management of Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention have been reported. Since the last update in 2018, several pivotal clinical trials in the field have been published. This document provides a focused updated of the 2018 recommendations. The group recommends that in patients with atrial fibrillation undergoing PCI, a non–vitamin K antagonist oral anticoagulant is the oral anticoagulation of choice. Dual antiplatelet therapy with aspirin and a P2Y 12 inhibitor should be given to all patients during the peri-PCI period (during inpatient stay, until time of discharge, up to 1 week after PCI, at the discretion of the treating physician), after which the default strategy is to stop aspirin and continue treatment with a P2Y 12 inhibitor, preferably clopidogrel, in combination with a non–vitamin K antagonist oral anticoagulant (ie, double therapy). In patients at increased thrombotic risk who have an acceptable risk of bleeding, it is reasonable to continue aspirin (ie, triple therapy) for up to 1 month. Double therapy should be given for 6 to 12 months with the actual duration depending on the ischemic and bleeding risk profile of the patient, after which patients should discontinue antiplatelet therapy and receive oral anticoagulation alone. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention A North American Perspective: 2021 Update FRONTIERS Downloaded from http://ahajournals.org by on February 24, 2021
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Related Documents
